Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...

Windtree Therapeutics, Inc. announced that it is preparing for an interim analysis of its SEISMiC C Phase 2 study of istaroxime, targeting results for July 2025. This global, placebo-controlled, ...

PARIS, France—From intra-aortic balloon pumps (IABPs) to synchronized extracorporeal membrane oxygenation (ECMO), a moderated poster session at EuroPCR 2019 focusing on interventions for cardiogenic ...

More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...

DETROIT (December 13, 2023) – Published results of a large, national heart attack study show that patients with a life-threatening complication known as cardiogenic shock survived at a significantly ...

The Company believes that this SCAI stage C study will be valuable for Phase 3 readiness of istaroxime in cardiogenic shock because these patients will be an important population for the target ...

Survival up with stage E patients funneled to specialized centers with MCS escalation ...

Differences in treatment, not sex, may explain the higher mortality rates observed among women who present with acute ...

Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the ...